| 2026-08-17 | Press release | Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies |
| 2026-06-01 | Press release | Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic R |
| 2026-05-08 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-27 | Press release | Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors |
| 2026-04-27 | Press release | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 |
| 2026-04-20 | Press release | Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, |
| 2026-03-19 | Press release | MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Acc |
| 2026-03-06 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-03 | Press release | Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference |
| 2026-02-24 | Press release | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 |
| 2026-02-24 | Press release | Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Poci |
| 2026-02-17 | Press release | Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Si |
| 2026-02-06 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-09 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-07 | Press release | Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-10 | Press release | Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants |
| 2025-12-08 | Press release | Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock |
| 2025-12-06 | Press release | Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Poci |
| 2025-12-05 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-12-02 | Press release | Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Ce |
| 2025-11-07 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-11-03 | Press release | Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th |
| Press release | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 |
| Press release | Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, |
| 2025-10-14 | Press release | Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ES |
| 2025-10-10 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-09-12 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-08-26 | Press release | Fulcrum Therapeutics to Participate in Upcoming September Investor Conferences |
| 2025-08-08 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| Press release | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 |
| 2025-07-29 | Press release | Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle |
| 2025-07-28 | Press release | Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle |
| 2025-07-11 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-06-06 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-05-29 | Press release | Fulcrum Therapeutics to Present at Upcoming Medical Meetings |
| 2025-05-29 | Press release | Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference |
| 2025-05-09 | Press release | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-05-08 | Press release | Fulcrum Therapeutics to Participate in Upcoming May Conferences |
| Press release | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 |
| Press release | Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, |